Common Heart Drug Recalled In 22 Countries For Possible Cancer Link

(CNN) — A common drug used to control blood pressure and help prevent heart failure is being recalled in 22 countries because it contains a chemical that poses a potential cancer risk. Valsartan is off-patent and is used as a component of other generic medicines. Novartis, the company that originally developed the drug, said Sandoz valsartan and valsartan/HCT film-coated tablets are being recalled since they “do not meet our high quality standards.” Pharmacies in the UK are advised to recall valsartan batches containing medicines made by Dexcel Pharma Ltd and Accord Healthcare. The recall involves about 2,300 batches that were sent to Germany, Norway, Finland, Sweden, Hungary, the Netherlands, Austria, Ireland, Bulgaria, Italy, Spain, Portugal, Belgium, France, Poland, Croatia, Lithuania, Greece, Canada, Bosnia and Herzegovina, Bahrain and Malta. Novartis spokesman Eric Althoff said that products sold in the United States are not affected by this recall. The US Food and Drug Administration says it is looking to see whether it “has any information to share at this time” and directed questions to the manufacturer, as it is “the best source of information about their product.” The problem was discovered during tests of batches of valsartan’s active pharmaceutical ingredient (API), as those from an external supplier contained an impurity. The European Medicines Agency reviewed medicines from the supplier, Zhejiang Huahai Pharmaceuti...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Valsartan Source Type: news

Related Links:

In a blog post last week, I shared an excerpt from the new book that Paul Cerrato and I just completed,The Transformative Power of Mobile Medicine. Here is a second excerpt from Chapter 3,  “Exploring the Strengths and Weaknesses of Mobile Health Apps.”Even patients who are fully engaged in their own care still need access to medical apps they can trust. The IQVIA Institute for Human Data Science has performed a detailed analysis of the clinical evidence supporting mobile health apps, rating their maturity and relative quality. Its rating scale places a single observational study near the bottom of th...
Source: Life as a Healthcare CIO - Category: Information Technology Source Type: blogs
CONCLUSION: Since the number of long-term survivants following diagnosis and treatment of malignant disease will continue to increase cardio-oncology will continue to evolve. Therefore a better understanding of potential cardiovascular effects of chemotherapeutic regiments and the earlier identification and treatment of high risk patients would focus research interest in the future. PMID: 30636595 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
Obesity has increased substantially in prevalence recently to become one of the major health burden around the world [1]. In the United States, almost 34.9% of adults and 16.9% of youth are obese [2]. Morbid obesity, defined as a body mass index (BMI) ≥40 kg/m2, is reported to be associated with lower quality of life and higher health-care costs. It is also well-established as a risk factor for illness including diabetes, cardiovascular disease, gastrointestinal disease and cancer [3]. Generally, life-style intervention, physical activity, anti -obesity drugs and bariatric surgery (BS) are main preventive and treatment ...
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Original articles Source Type: research
This study suggests that advantages and disadvantages vary by environment and diet, however, which might explain why evolution has selected for multiple haplogroups rather than one dominant haplogroup. This is all interesting, but none of it stops the research community from engineering a globally better-than-natural human mitochondrial genome, and then copying it into the cell nucleus as a backup to prevent the well-known contribution of mitochondrial DNA damage to aging. Further, nothing stops us from keeping the haplogroups we have and rendering the effects of variants small and irrelevant through the development...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Introduction to the Theme "New Therapeutic Targets". Annu Rev Pharmacol Toxicol. 2019 Jan 06;59:15-20 Authors: Insel PA, Amara SG, Blaschke TF, Meyer UA Abstract "New Therapeutic Targets" is the theme of articles in the Annual Review of Pharmacology and Toxicology, Volume 59. Reviews in this volume discuss targets for a variety of conditions in need of new therapies, including type 2 diabetes, heart failure with preserved ejection fraction, obesity, thyroid-associated ophthalmopathy, tinnitus, multiple sclerosis, Parkinson's disease and other neurodegenerative diseases, pain, depre...
Source: Annual Review of Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Tags: Annu Rev Pharmacol Toxicol Source Type: research
(CNN) — The recall of popular heart drugs has expanded yet again. The US Food and Drug Administration said Thursday that Torrent Pharmaceuticals has added eight additional lots of losartan potassium tablets to its recall list. Losartan potassium is a drug used to control high blood pressure. It is also used to treat kidney disease in patients with diabetes. This recall includes 30-, 90- and 1,000-count bottles of 100-milligram tablets; 30-, 90- and 1,000-count bottles of 50-milligram tablets; and 90-count bottles of 25-milligram tablets. Torrent is recalling only these particular losartan potassium tablets. Tests fou...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News CNN Recall Valsartan Source Type: news
AbstractDiuretic resistance (DR) is common in patients with decompensated heart failure (HF), and is associated with adverse outcomes. To determine the prevalence of DR and its impact on survival among patients with decompensated HF, we prospectively evaluated the prevalence and influence on prognosis of DR (defined as persistent congestion despite  ≥ 80 mg of furosemide per day) in a cohort of elderly patients from the Spanish HF registry (RICA) admitted for an acute decompensation of HF. Patients with new-onset HF were excluded. From the global cohort of 2067 patients, 435 (21%; 95% CI 19.3%–2...
Source: Internal and Emergency Medicine - Category: Emergency Medicine Source Type: research
AbstractThree further cardiovascular (CV) outcome studies of glucose-lowering drugs (linagliptin, albiglutide and dapagliflozin) have recently been published, adding to the twelve earlier within-class studies. The linagliptin study (CARMELINA) recruited people with renal disease as well as prior CV events and confirms the overall CV safety (and other safety) of the dipeptidylpeptidase-4 (DPP4) inhibitors, with no heart failure risk associated with this agent. However, taken together with the findings from two previous studies of DPP4 inhibitors (sitagliptin and saxagliptin), the three DPP4 inhibitor CV outcome trials (CVOT...
Source: Diabetologia - Category: Endocrinology Source Type: research
(AI), also known as anemia of chronic disease (ACD), is regarded as the most frequent anemia in hospitalized and chronically ill patients. It is prevalent in patients with diseases that cause prolonged immune activation, including infection, autoimmune diseases, and cancer. More recently, the list has grown to include chronic kidney disease, congestive heart failure, chronic pulmonary diseases, and obesity. Inflammation-inducible cytokines and the master regulator of iron homeostasis, hepcidin, block intestinal iron absorption and cause iron retention in reticuloendothelial cells, resulting in iron-restricted erythropoies...
Source: Blood - Category: Hematology Authors: Tags: Red Cells, Iron, and Erythropoiesis, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
Discussion of Mitochondrial Hormesis as an Approach to Slow Aging Cornelis (Cees) Wortel, Ichor Therapeutics Chief Medical Officer, on Rejuvenation Research and Its Engagement with the Established Regulatory System An Interview with a Programmed Aging Theorist An Interview with Reason at the Life Extension Advocacy Foundation An Interview on Mitochondrial Damage and Dysfunction in Aging An Interview with Vadim Gladyshev on Research into the Causes of Aging An Interview with Jim Mellon, and Update on Juvenescence A Lengthy Interview with Aubrey de Grey of the SENS Research Foundation An Interview with Peter de Keize...
Source: Fight Aging! - Category: Research Authors: Tags: Healthy Life Extension Community Source Type: blogs
More News: Austria Health | Bahrain Health | Belgium Health | Bosnia and Herzegovina Health | Bulgaria Health | Canada Health | Cancer | Cancer & Oncology | Cardiology | Chemistry | China Health | Croatia Health | Diovan | European Medicines Agency (EMA) | Finland Health | Fish | France Health | Germany Health | Greece Health | Health | Heart | Heart Failure | Hungary Health | International Medicine & Public Health | Ireland Health | Italy Health | Lithuania Health | Liver | Malta Health | Middle East Health | Netherlands Health | Norway Health | Organic | Pharmaceuticals | Poland Health | Portugal Health | Respiratory Medicine | Spain Health | Sports Medicine | Study | Sweden Health | Toxicology | Urology & Nephrology | USA Health